­
medigraphic.com
ISSN 2448-5640 (Print)
Diario Oficial de la Sociedad Mexicana de Cirugía Cardiaca, A.C., y del Colegio Mexicano de Cirugía Cardiovascular y Torácica, A.C.

2022, Number 3

<< Back Next >>

Cir Card Mex 2022; 7 (3)

Annuloplasty ring as a sine qua non condition in mitral valve repair renders transcatheter edge-toedge repair an imperfect technique to treat mitral valve regurgitation

García-Villarreal OA

Language: Spanish
References: 36
Page: 50-54
PDF size: 284.18 Kb.


ABSTRACT

Transcatheter edge-to-edge mitral valve repair to treat mitral regurgitation, has emerged as one of the most impactful cutting-edge technologies in structural interventional cardiology in recent years. Surgical edge-to-edge mitral valve repair underpins the concept of transcatheter edge-to-edge mitral valve repair. However, of particular importance, is the main difference between both techniques. While the annuloplasty ring is a sine qua non condition for surgical mitral valve repair, the transcatheter edge-to-edge mitral valve repair is a ringless therapy. Therefore, the transcatheter edge-to-edge mitral valve repair is only a partially effective treatment for mitral regurgitation, especially in the long-term. As yet, the criteria governing the use of the transcatheter edge-to-edge mitral valve repair as an isolated procedure without annuloplasty ring, are practically unknown. Hence, special emphasis should be devoted on the potential implications that an imperfect technique such as transcatheter edge-to-edge therapy may have on patient's survival, quality of life and unplanned rehospitalization for heart failure rates in the long-term.


REFERENCES

  1. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, etal. 2020 ACC/AHA Guideline for the Management of Patients with Valvular HeartDisease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143:e35-e71.

  2. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al;ESC/EACTS Scientific Document Group; ESC Scientific Document Group. 2021ESC/EACTS Guidelines for the management of valvular heart disease. Eur HeartJ. 2022;43:561-632.

  3. Carpentier A. La valvuloplastie reconstructive. Une nouvelle technique de valvuloplastiemitrale [Reconstructive valvuloplasty. A new technique of mitral valvuloplasty].Presse Med. 1969;77:251-253.

  4. Carpentier A, Deloche A, Dauptain J, Soyer R, Blondeau P, Piwnica A, et al. Anew reconstructive operation for correction of mitral and tricuspid insufficiency. JThorac Cardiovasc Surg. 1971;61:1-13.

  5. Carpentier A, Relland J, Deloche A, Fabiani JN, D'Allaines C, Blondeau P, etal. Conservative management of the prolapsed mitral valve. Ann Thorac Surg.1978;26:294-302.

  6. Carpentier A, Chauvaud S, Fabiani JN, Deloche A, Relland J, Lessana A, et al.Reconstructive surgery of mitral valve incompetence: ten-year appraisal. J ThoracCardiovasc Surg. 1980;79:338-348.

  7. Carpentier A. Cardiac valve surgery--the "French correction". J Thorac Cardio-vasc Surg. 1983;86:323-337.

  8. Carpentier A, Adams D, Filsoufi F (Eds) (2010). Carpentier's ReconstructiveValve Surgery. From Valve Analysis to Valve Reconstruction. 1st Edition. EditorialSaunders (W.B.) Co Ltd. Elsevier. ISBN 9780721691688.

  9. Alfieri O, De Bonis M, La Canna G. (Eds.). (2015). Edge-to-Edge Mitral Repair.From a surgical to a percutaneous approach. Springer International PublishingSwitzerland 2015. Electronic version. ISBN978-3-319-19893-4 (eBook).

  10. Gillinov AM, Cosgrove DM, Blackstone EH, Diaz R, Arnold JH, Lytle BW, et al.Durability of mitral valve repair for degenerative disease. J Thorac CardiovascSurg. 1998;116:734-743.

  11. Gillinov AM, Cosgrove DM. Mitral valve repair for degenerative disease. J HeartValve Dis. 2002;11 Suppl 1:S15-S20.

  12. David TE, Armstrong S, McCrindle BW, Manlhiot C. Late outcomes of mitralvalve repair for mitral regurgitation due to degenerative disease. Circulation.2013;127:1485-1492.

  13. David TE. Durability of mitral valve repair for mitral regurgitation due to degenerativemitral valve disease. Ann Cardiothorac Surg. 2015;4:417-421.

  14. Suri RM, Clavel MA, Schaff HV, Michelena HI, Huebner M, Nishimura RA,et al. Effect of Recurrent Mitral Regurgitation Following Degenerative MitralValve Repair: Long-Term Analysis of Competing Outcomes. J Am Coll Cardiol.2016;67:488-498.

  15. Alfieri O, Maisano F, De Bonis M, Stefano PL, Torracca L, Oppizzi M, et al.The double-orifice technique in mitral valve repair: a simple solution for complexproblems. J Thorac Cardiovasc Surg. 2001;122:674-681.

  16. De Bonis M, Lapenna E, Taramasso M, La Canna G, Buzzatti N, Pappalardo F, etal. Very long-term durability of the edge-to-edge repair for isolated anterior mitralleaflet prolapse: up to 21 years of clinical and echocardiographic results. J ThoracCardiovasc Surg. 2014;148:2027-2032.

  17. De Bonis M, Lapenna E, Maisano F, Barili F, La Canna G, Buzzatti N, et al.Long-term results (≤18 years) of the edge-to-edge mitral valve repair without annuloplastyin degenerative mitral regurgitation: implications for the percutaneousapproach. Circulation. 2014;130(11 Suppl 1):S19-24.

  18. De Bonis M, Lapenna E, Pozzoli A, Giacomini A, Alfieri O. Edge-to-edge surgicalmitral valve repair in the era of MitraClip: what if the annuloplasty ring is missed?Curr Opin Cardiol 2015;30:155-160.

  19. Del Forno B, Castiglioni A, Sala A, Geretto A, Giacomini A, Denti P, et al. Mitralvalve annuloplasty. Multimed Man Cardiothorac Surg. 2017.doi: 10.1510/mmcts.2017.016. 11.

  20. Maisano F, Franzen O, Baldus S, Schäfer U, Hausleiter J, Butter C, et al. Percutaneousmitral valve interventions in the real world: early and 1-year results fromthe ACCESS-EU, a prospective, multicenter, nonrandomized post-approval studyof the MitraClip therapy in Europe. J Am Coll Cardiol. 2013;62:1052-1061.

  21. Feldman T, Kar S, Elmariah S, Smart SC, Trento A, Siegel RJ, et al; EVERESTII Investigators. Randomized Comparison of Percutaneous Repair and Surgeryfor Mitral Regurgitation: 5-Year Results of EVEREST II. J Am Coll Cardiol.2015;66:2844-2854.

  22. Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, et al; COAPTInvestigators. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. NEngl J Med. 2018;379:2307-2318.

  23. COAPT. A randomized trial of transcatheter mitral valve leaflet approximationin patients with heart failure and secondary mitral regurgitation. Stone GW, onbehalf of Mack M, Abraham W, Lindenfeld J, and the COAPT Investigators.TCT 2018 Presentation Slides. Disponible en: https://www.acc.org/-/media/Clinical/PDF-Files/Approved-PDFs/2018/09/21/TCT-2018-Slides/Sept23-Sun/115pmET_COAPT-tct-2018.pdf. Último acceso: Mar 17, 2022.

  24. Obadia JF, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, et al; MITRA-FR Investigators. Percutaneous Repair or Medical Treatment for SecondaryMitral Regurgitation. N Engl J Med. 2018;379:2297-2306.

  25. Mack M, Carroll JD, Thourani V, Squiers J, Manandhar P, Deeb GM, et al. TranscatheterMitral Valve Therapy in the United States: A Report from the STS/ACCTVT Registry. Ann Thorac Surg. 2022;113:337-365.

  26. Adamo M, Grasso C, Capodanno D, Rubbio AP, Scandura S, Giannini C, et al.Five-year clinical outcomes after percutaneous edge-to-edge mitral valve repair:Insights from the multicenter GRASP-IT registry. Am Heart J. 2019;217:32-41.

  27. Reichart D, Kalbacher D, Rübsamen N, Tigges E, Thomas C, Schirmer J, et al.The impact of residual mitral regurgitation after MitraClip therapy in functionalmitral regurgitation. Eur J Heart Fail. 2020;22:1840-1848.

  28. Buzzatti N, De Bonis M, Denti P, Barili F, Schiavi D, Di Giannuario G, et al. Whatis a "good" result after transcatheter mitral repair? Impact of 2+ residual mitralregurgitation. J Thorac Cardiovasc Surg. 2016;151:88-96.

  29. Buzzatti N, Denti P, Scarfò IS, Giambuzzi I, Schiavi D, Ruggeri S, et al. Midtermoutcomes (up to 5 years) of percutaneous edge-to-edge mitral repair in thereal-world according to regurgitation mechanism: A single-center experience.Catheter Cardiovasc Interv. 2019;94:427-435.

  30. Weber M, Öztürk C, Taramasso M, Pozzoli A, Pfister R, Wösten M, et al. Leafletedge-to-edge treatment versus direct annuloplasty in patients with functional mitralregurgitation. EuroIntervention. 2019;15:912-918.

  31. Melica B, Braga P, Ribeiro J, Pires-Morais G, Fonte Boa A, Guerreiro C, et al.Transseptal Mitral Annuloplasty With the AMEND System: First-in-Human Experience.JACC Cardiovasc Interv. 2022;15:e3-e5.

  32. Kaneko T, Newel PC, Nisivaco S, Yoo SGK, Hirji SA, Hou H, et al. Incidence,Characteristics, and Outcomes of Reintervention After Mitral Transcatheter Edge-To-Edge Repair. J Thorac Cardiovasc Surg (2022). Published: April 12, 2022.DOI:https://doi.org/10.1016/j.jtcvs.2022.02.060.

  33. Kaneko T, Hirji S, Zaid S, Lange R, Kempfert J, Conradi L, et al; CUTTING-EDGEInvestigators. Mitral Valve Surgery After Transcatheter Edge-to-Edge Repair:Mid-Term Outcomes from the CUTTING-EDGE International Registry. JACCCardiovasc Interv. 2021;14:2010-2021.

  34. Chikwe J, O'Gara P, Fremes S, Sundt TM 3rd, Habib RH, Gammie J, et al. MitralSurgery After Transcatheter Edge-to-Edge Repair: Society of Thoracic SurgeonsDatabase Analysis. J Am Coll Cardiol. 2021;78:1-9.

  35. Dayan V, Garcia-Villarreal OA, Escobar A, Ferrari J, Quintana E, Marin-CuartasM, et al. The Latin American Association of Cardiac and Endovascular Surgerystatement regarding the recently released American Heart Association/AmericanCollege of Cardiology Guideline for the Management of Patients with ValvularHeart Disease 2020. J Thorac Cardiovasc Surg. 2021;162:584-586.

  36. García-Villarreal OA. Transcatheter edge-to-edge valve repair in functional mitralregurgitation. Eur J Cardiothorac Surg. 2021: ezab521. doi: 10.1093/ejcts/ezab521.




2020     |     www.medigraphic.com

    Este sitio utiliza cookies   Estoy de acuerdo